Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RGLS [NASD]
Regulus Therapeutics Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.55 Insider Own4.70% Shs Outstand47.82M Perf Week-6.52%
Market Cap101.50M Forward P/E- EPS next Y-0.38 Insider Trans- Shs Float36.65M Perf Month-30.27%
Income-15.70M PEG- EPS next Q-0.09 Inst Own39.10% Short Float18.21% Perf Quarter8.40%
Sales10.00M P/S10.15 EPS this Y58.20% Inst Trans200.26% Short Ratio2.02 Perf Half Y136.48%
Book/sh0.54 P/B2.39 EPS next Y-5.70% ROA-48.50% Target Price1.33 Perf Year162.20%
Cash/sh0.40 P/C3.26 EPS next 5Y39.60% ROE-109.90% 52W Range0.42 - 2.32 Perf YTD-4.44%
Dividend- P/FCF- EPS past 5Y49.00% ROI-46.10% 52W High-47.84% Beta2.32
Dividend %- Quick Ratio3.20 Sales past 5Y-13.60% Gross Margin- 52W Low186.59% ATR0.19
Employees24 Current Ratio3.20 Sales Q/Q27677.80% Oper. Margin- RSI (14)39.89 Volatility16.47% 11.55%
OptionableYes Debt/Eq0.18 EPS Q/Q88.10% Profit Margin- Rel Volume0.28 Prev Close1.29
ShortableYes LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume3.31M Price1.21
Recom3.00 SMA20-19.25% SMA50-21.51% SMA20024.14% Volume728,764 Change-6.20%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Apr-15-21 08:07AM  
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Apr-07-21 08:07AM  
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
PR Newswire
Mar-10-21 04:03AM  
Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101%
Simply Wall St.
Mar-09-21 04:07PM  
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
PR Newswire +7.03%
Mar-05-21 04:07PM  
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
PR Newswire +13.04%
Mar-04-21 12:30PM  
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know
Zacks -9.45%
Feb-10-21 08:07AM  
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Jan-27-21 08:07AM  
Regulus Announces Addition to Board of Directors
PR Newswire -10.32%
Jan-05-21 08:07AM  
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
PR Newswire
Dec-09-20 08:54AM  
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
Zacks
Dec-08-20 08:07AM  
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity
PR Newswire +15.19%
Dec-02-20 07:00AM  
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
PR Newswire
Dec-01-20 08:35AM  
Regulus Therapeutics Announces Private Placement of Equity
PR Newswire +11.09%
Nov-29-20 02:33PM  
Should I Buy Regulus Therapeutics Inc (RGLS)?
Insider Monkey
Nov-05-20 05:25PM  
Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:07PM  
Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates
PR Newswire
Nov-03-20 12:31PM  
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks
Nov-02-20 08:07AM  
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi
PR Newswire
Oct-15-20 08:07AM  
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire
Oct-13-20 08:07AM  
Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi
PR Newswire +8.38%
Sep-11-20 08:07AM  
Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
PR Newswire
Sep-08-20 08:28AM  
What You Need To Know About The Regulus Therapeutics Inc. (NASDAQ:RGLS) Analyst Downgrade Today
Simply Wall St.
Sep-03-20 08:07AM  
Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference
PR Newswire
Aug-31-20 08:07AM  
Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements
PR Newswire -7.00%
Aug-13-20 06:05PM  
Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates
Zacks -6.10%
04:07PM  
Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
PR Newswire
Aug-06-20 12:30PM  
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks -6.40%
08:07AM  
Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PR Newswire
Aug-03-20 08:07AM  
Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
PR Newswire
Jul-29-20 08:07AM  
Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire +5.22%
Jul-22-20 08:07AM  
Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR Newswire -11.58%
Jun-12-20 08:01AM  
Analysts' Revenue Estimates For Regulus Therapeutics Inc. (NASDAQ:RGLS) Are Surging Higher
Simply Wall St. +10.47%
May-14-20 04:07PM  
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
PR Newswire
May-07-20 12:30PM  
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Mar-12-20 04:37PM  
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
PR Newswire -13.54%
Mar-09-20 12:30PM  
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks
Feb-13-20 04:30PM  
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
PR Newswire
Jan-21-20 07:47AM  
How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility
Simply Wall St. +8.26%
Dec-22-19 07:44PM  
Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS)
Insider Monkey
Dec-16-19 08:00AM  
Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
PR Newswire -6.78%
Nov-18-19 08:07AM  
Regulus Therapeutics to Present at the Stifel Healthcare Conference
PR Newswire
Nov-15-19 01:37PM  
Analysts Are Upgrading Regulus Therapeutics Inc. After Its Latest Results
Simply Wall St. -5.78%
Nov-12-19 05:55PM  
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
Zacks
04:05PM  
Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates
PR Newswire
Nov-07-19 10:30AM  
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks
Oct-16-19 04:15PM  
Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
PR Newswire
Sep-20-19 01:30PM  
Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out
Simply Wall St.
Sep-12-19 08:00AM  
Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
PR Newswire +5.26%
Sep-03-19 04:10PM  
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
PR Newswire +8.87%
Aug-29-19 04:10PM  
Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
PR Newswire
Aug-08-19 07:20PM  
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
Zacks
04:10PM  
Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
PR Newswire
Aug-06-19 02:50PM  
What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own?
Simply Wall St.
Aug-01-19 10:33AM  
Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know
Zacks
Jul-30-19 08:00AM  
Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
PR Newswire -11.47%
Jul-29-19 11:33AM  
Penny Stocks to Buy Using Technical Analysis for August 2019
Investopedia
Jul-23-19 06:30PM  
Regulus Therapeutics Announces RGLS4326 Program Update
PR Newswire
Jun-11-19 05:00AM  
Regulus Announces New Additions to Board of Directors
PR Newswire
May-10-19 05:39AM  
Regulus: 1Q Earnings Snapshot
Associated Press +6.40%
May-09-19 04:05PM  
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
PR Newswire
May-07-19 04:05PM  
Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
PR Newswire
May-06-19 09:15AM  
Regulus Therapeutics Announces Restructuring of Term Loan
PR Newswire +16.67%
09:00AM  
Regulus Therapeutics Announces Private Placement of Equity
PR Newswire
May-02-19 10:32AM  
Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know
Zacks -5.20%
Apr-08-19 08:00AM  
Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress 2019
PR Newswire
Mar-28-19 09:45AM  
Four Healthcare Stocks Getting a Boost on Thursday
ACCESSWIRE -6.36%
Mar-18-19 08:53AM  
Regulus: 4Q Earnings Snapshot
Associated Press
08:00AM  
Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
PR Newswire
Mar-15-19 06:00PM  
Regulus Announces Transition of Research Leadership
PR Newswire -19.86%
Jan-07-19 08:00AM  
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
PR Newswire
Jan-04-19 04:05PM  
Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
PR Newswire +11.11%
Dec-20-18 09:56AM  
Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
Simply Wall St.
Nov-28-18 07:35AM  
Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement
GlobeNewswire +6.00%
Nov-19-18 08:00AM  
Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
PR Newswire
Nov-08-18 06:40PM  
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
Zacks
05:38PM  
Regulus: 3Q Earnings Snapshot
Associated Press
04:05PM  
Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
PR Newswire
Nov-06-18 07:30AM  
Regulus Announces Successful Restructuring of Sanofi Collaboration
PR Newswire +6.38%
Oct-25-18 04:05PM  
Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
PR Newswire
Oct-23-18 11:30AM  
3 Healthcare Stocks To Watch On Tuesday
ACCESSWIRE +15.85%
08:35AM  
The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
Benzinga
Oct-22-18 04:05PM  
Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
PR Newswire
Oct-18-18 04:05PM  
Regulus Regains Compliance with NASDAQ Listing Requirements
PR Newswire
Oct-17-18 07:45AM  
Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook Fundamental Analysis, Calculating Forward Movement
GlobeNewswire
Oct-04-18 08:05AM  
Regulus Therapeutics Announces Reverse Stock Split
PR Newswire -7.54%
Oct-02-18 04:05PM  
Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
PR Newswire -6.05%
Sep-27-18 04:05PM  
Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
PR Newswire
Sep-26-18 04:05PM  
Regulus Provides Pipeline Updates
PR Newswire
Sep-19-18 02:22PM  
Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?
Simply Wall St.
Aug-23-18 12:50PM  
These Biotech Stocks Are Moving Higher in August
ACCESSWIRE
Aug-09-18 06:10PM  
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
Zacks -9.42%
05:05PM  
Regulus: 2Q Earnings Snapshot
Associated Press
04:05PM  
Regulus Reports Second Quarter 2018 Financial Results and Recent Updates
PR Newswire
Jul-09-18 09:13AM  
Regulus Stock Plunges on Cash Concerns Despite Restructuring
Zacks
Jul-05-18 05:00PM  
Regulus Announces Strategic Update and Corporate Restructuring
PR Newswire
07:35AM  
Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities
ACCESSWIRE
Jul-03-18 12:38PM  
Gaithersburg biotech raising $1M to stop cancer tumors in their tracks
American City Business Journals
Jun-12-18 07:45AM  
New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser Factors of Influence, Major Initiatives and Sustained Production
GlobeNewswire
May-17-18 07:40AM  
Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust Future Expectations, Projections Moving into 2018
GlobeNewswire
May-10-18 11:46PM  
Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT
Thomson Reuters StreetEvents
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aker Christopher RaySr. VP & General CounselFeb 16Sale1.728281,42442,614Feb 17 05:23 PM
Hagan Joseph PPresident and CEOFeb 16Sale1.724,1447,128485,756Feb 17 05:23 PM
Sonsini Peter W.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:13 PM
Walker Paul Edward10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:14 PM
SANDELL SCOTT D10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
MAKOWER JOSHUA10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
Florence Anthony A. Jr.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Makhzoumi Mohamad10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:11 PM
Chang Carmen10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Behbahani Ali10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:09 PM
BASKETT FOREST10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:08 PM
Growth Equity Opportunities V,10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:06 PM
Aker Christopher RaySr. VP & General CounselNov 16Sale0.5287645625,762Nov 18 04:10 PM
Hagan Joseph PPresident and CEONov 16Sale0.526,0943,176215,994Nov 18 04:09 PM
Aker Christopher RaySr. VP & General CounselAug 14Sale0.6087252826,638Aug 17 08:21 PM
Hagan Joseph PPresident and CEOAug 14Sale0.604,2452,568222,088Aug 17 08:22 PM
Hagan Joseph PPresident and CEOMay 15Sale0.634,4262,774226,333May 18 04:28 PM
Aker Christopher RaySr. VP & General CounselMay 15Sale0.6390957027,510May 18 04:27 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.